| Literature DB >> 33393505 |
Daxing Gao1,2,3, Michael J Ciancanelli1,4, Peng Zhang1, Oliver Harschnitz5,6, Vincent Bondet7, Mary Hasek1, Jie Chen1, Xin Mu8, Yuval Itan9,10, Aurélie Cobat11,12, Vanessa Sancho-Shimizu11,12,13, Benedetta Bigio1, Lazaro Lorenzo11,12, Gabriele Ciceri5,6, Jessica McAlpine5,6, Esperanza Anguiano14, Emmanuelle Jouanguy1,11,12, Damien Chaussabel14,15,16, Isabelle Meyts17,18,19, Michael S Diamond20, Laurent Abel1,11,12, Sun Hur8, Gregory A Smith21, Luigi Notarangelo22, Darragh Duffy7, Lorenz Studer5,6, Jean-Laurent Casanova1,11,12,23,24, Shen-Ying Zhang1,11,12.
Abstract
Human herpes simplex virus 1 (HSV-1) encephalitis can be caused by inborn errors of the TLR3 pathway, resulting in impairment of CNS cell-intrinsic antiviral immunity. Deficiencies of the TLR3 pathway impair cell-intrinsic immunity to vesicular stomatitis virus (VSV) and HSV-1 in fibroblasts, and to HSV-1 in cortical but not trigeminal neurons. The underlying molecular mechanism is thought to involve impaired IFN-α/β induction by the TLR3 recognition of dsRNA viral intermediates or by-products. However, we show here that human TLR3 controls constitutive levels of IFNB mRNA and secreted bioactive IFN-β protein, and thereby also controls constitutive mRNA levels for IFN-stimulated genes (ISGs) in fibroblasts. Tlr3-/- mouse embryonic fibroblasts also have lower basal ISG levels. Moreover, human TLR3 controls basal levels of IFN-β secretion and ISG mRNA in induced pluripotent stem cell-derived cortical neurons. Consistently, TLR3-deficient human fibroblasts and cortical neurons are vulnerable not only to both VSV and HSV-1, but also to several other families of viruses. The mechanism by which TLR3 restricts viral growth in human fibroblasts and cortical neurons in vitro and, by inference, by which the human CNS prevents infection by HSV-1 in vivo, is therefore based on the control of early viral infection by basal IFN-β immunity.Entities:
Keywords: Immunology; Infectious disease; Innate immunity
Mesh:
Substances:
Year: 2021 PMID: 33393505 PMCID: PMC7773389 DOI: 10.1172/JCI134529
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 19.456